About Us

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct® platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered in Lexington, Massachusetts, and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

News Releases

16 11 / 2026
Reports third quarter 2026 total revenue of $9.5 million, representing 22% growth compared to the third quarter of 2025 Placed 7 Growth Direct systems and completed 12 validations in the third quarter of 2026 Reports record third quarter 2026 total gross margin of 25%, an increase of 16 percentage